Trial Profile

A Phase I Study of Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Duvelisib (Primary)
Indications Adult T-cell leukaemia-lymphoma; B-cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Large granular lymphocytic leukaemia; Mantle-cell lymphoma; Panniculitis; T-cell lymphoma; T-cell prolymphocytic leukaemia
Focus Adverse reactions

Most Recent Events

12 Mar 2025 Status changed from active, no longer recruiting to completed.
06 Feb 2025 Planned End Date changed from 1 Jan 2025 to 1 Jun 2025.
06 Nov 2024 According to Secura Bio media release, the company will present data from this study at the upcoming 2024 American Society of Hematology (ASH) Annual Meeting taking place on December 7-10, 2024 in San Diego, CA.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com